Literature DB >> 10843823

The natural history of prevalent ischaemic heart disease in middle-aged men.

F C Lampe1, P H Whincup, S G Wannamethee, A G Shaper, M Walker, S Ebrahim.   

Abstract

OBJECTIVE: To describe the long-term outcome of different forms of symptomatic and asymptomatic ischaemic heart disease in middle-aged men.
METHODS: 7735 men aged 40-59, randomly selected from 24 general practices in Britain were classified into one of seven ischaemic heart disease groups according to a questionnaire and electrocardiogram (ECG): I=diagnosed myocardial infarction; II=unrecognized myocardial infarction; III= diagnosed angina; IV=angina symptoms; V=possible myocardial infarction symptoms; VI=ECG ischaemia or possible myocardial infarction; VII=no evidence of ischaemic heart disease. The association of disease group with a range of fatal and non-fatal outcomes during 15 years of follow-up was assessed.
RESULTS: At baseline 25% of men had evidence of ischaemic heart disease (groups I-VI). Risks of major ischaemic heart disease events, total and cardiovascular mortality, stroke, and major cardiovascular events tended to increase strongly from group VII to I. Diagnosed myocardial infarction was associated with a much poorer prognosis than all other groups (including unrecognized infarction) for all cardiovascular outcomes other than stroke. The relative risk associated with ischaemic heart disease at baseline declined dramatically over time. However, men with myocardial infarction who survived event-free for 10 years continued to experience a high excess risk in the subsequent 5 years, in contrast to event-free survivors of angina and other ischaemic heart disease. Adjusted to an average age of 50, the percentage of men surviving for 15 years free of a new major cardiovascular event was 44 for diagnosed myocardial infarction, 52 for unrecognized myocardial infarction, 66 for diagnosed angina, 68 for angina symptoms, 73 for possible myocardial infarction symptoms, 73 for ECG ischaemia, and 79 for no ischaemic heart disease. Comparison of outcome between prevalent and incident myocardial infarction illustrated the improved prognosis of men surviving the initial years after their event.
CONCLUSIONS: Differing manifestations of prevalent ischaemic heart disease are associated with widely differing outcome, and the majority of middle-aged men in the community who have evidence of ischaemic heart disease short of myocardial infarction survive for 15 years without heart attack or stroke. The excess risk associated with myocardial infarction appears more persistent than that associated with angina and other ischaemic heart disease, remaining high even after 10 years of event-free survival.

Entities:  

Mesh:

Year:  2000        PMID: 10843823     DOI: 10.1053/euhj.1999.1866

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  22 in total

1.  Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography.

Authors:  Khawaja Afzal Ammar; Ravindrakumar Makwana; Steven J Jacobsen; Jan A Kors; John C Burnett; Margaret M Redfield; Barbara P Yawn; Richard J Rodeheffer
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-01       Impact factor: 1.468

2.  Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.

Authors:  Anju Parthan; Kevin J Leahy; Amy K O'Sullivan; Olga A Iakoubova; Lance A Bare; James J Devlin; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

3.  Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.

Authors:  Michael Pignone; Stephanie Earnshaw; Cheryl McDade; Mark J Pletcher
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

4.  A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study.

Authors:  N F Murphy; S Stewart; C L Hart; K MacIntyre; D Hole; J J V McMurray
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

5.  A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.

Authors:  Mark Lamotte; Lieven Annemans; Pawel Kawalec; York Zoellner
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Cost-effectiveness of diagnostic evaluation strategies for individuals with stable chest pain syndrome and suspected coronary artery disease.

Authors:  James K Min; Amanda Gilmore; Erica C Jones; Daniel S Berman; Wijnand J Stuijfzand; Leslee J Shaw; Ken O'Day; Ibrahim Danad
Journal:  Clin Imaging       Date:  2017-02-10       Impact factor: 1.605

7.  Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.

Authors:  Virginia M Rosen; Douglas C A Taylor; Hemangi Parekh; Ankur Pandya; David Thompson; Andreas Kuznik; David D Waters; Michael Drummond; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Authors:  Miao Wang; Andrew E Moran; Jing Liu; Pamela G Coxson; Paul A Heidenreich; Dongfeng Gu; Jiang He; Lee Goldman; Dong Zhao
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

9.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men.

Authors:  S G Wannamethee; P H Whincup; A G Shaper; A Rumley; L Lennon; G D O Lowe
Journal:  J Thromb Haemost       Date:  2009-08-11       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.